SGIOY Shionogi & Co., Ltd.

OTC
$9.70

Shionogi & Co., Ltd. (SGIOY) is expected to report earnings on January 28, 2027, before the market open. The consensus earnings estimate is $0.18 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +0.6% since its last earnings release on October 29, 2026.

Shionogi & Co., Missed Consensus Estimates
Thursday, October 29, 2026 · 12:00 AM ET
Earnings Date
3rd Quarter, Dec 2026
Jan 28
Thursday · Before Open
Earnings Whisper
-
vs $0.18
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $9.69

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Shionogi & Co., Ltd.

Shionogi & Co., Ltd. engages in the research, development, manufacture and distribution of pharmaceuticals, diagnostic reagents, and medical devices. Its primary products Tivicay for HIV treatment; Mulpleta for the treatment of thrombocytopenia; Xofluza, an influenza drug; Symproic for opioid-induced constipation treatment and Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment. Shionogi & Co., Ltd. is based in Osaka, Japan.

Sector

Healthcare

Industry

Drug Manufacturers/Other

Charts powered in part by Lightweight Charts™ by TradingView.